tetracycline and clindamycin-phosphate

A new topical antibiotic preparation, clindamycin in a lotion base, was compared with oral tetracycline in the treatment of rosacea. Forty-three patients clinically diagnosed as having rosacea were examined in an investigator-blinded study.. Patients used topical clindamycin lotion applied twice daily or the usual oral dose of tetracycline hydrochloride (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks). Patients' lesions were examined clinically at 3-week intervals over a period of 12 weeks.. Topical clindamycin treatment produced similar clinical results to oral tetracycline and was superior in the eradication of pustules.. These results show topical clindamycin in a lotion base to be a safe and effective alternative to oral tetracycline therapy in the treatment of rosacea.

Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Clindamycin; Double-Blind Method; Follow-Up Studies; Humans; Middle Aged; Rosacea; Tetracycline

Sixty patients (aged 12-30 years) were enrolled in a 12-week, double-blind, randomized study to compare the efficacy of clindamycin phosphate 1% topical solution with oral tetracycline for the treatment of moderate acne. Forty-four patients (22 in each group) were evaluable. All patients experienced significant reductions in numbers of pustules, papules and inflamed nodules, and there were no significant differences between the two groups. Both treatment regimens were well tolerated, and no systemic side-effects were reported. Topical clindamycin phosphate 1% is considered a safe and effective alternative to oral tetracycline for the treatment of moderate acne vulgaris.

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Child; Clindamycin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Random Allocation; Tetracycline

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Clindamycin; Corynebacterium Infections; Double-Blind Method; Female; Humans; Male; Microbial Sensitivity Tests; Random Allocation; Tetracycline

This study consists on an eight week completely randomized investigator blind trial designed to compare the relative efficacy and tolerance of clindamycin phosphate topical solution and tetracycline in the treatment of patients with mild to moderate acne vulgaris. Patients were seen at baseline, weeks 2, 4, 6 and 8. Of the forty-five case report forms received in house, thirty-four are considered to be evaluable. Seven patients failed the entry criteria, two patients were lost to follow-up and two patients left due to lack of tolerance to the medication. All patients receiving medication were examined for both local and global tolerance indices. Within group analyses show significant improvement for both medication groups with respect to the continuous efficacy parameters: inflammatory lesions, pustules, papules and comedo counts. After adjusting for initial baseline differences, no differences between the two groups arose for these variables. The investigating physician on the average judged clindamycin phosphate to be significantly more efficacious than tetracycline trends for the patients evaluation supported these results. Throughout the study, the incidence of peeling, erythema and itching was low and similar for both groups. Two tetracycline patients did however terminate participation in the study due to itching. Significantly more patients receiving tetracycline complained of a burning sensation. No diarrhea or other side effects were recorded.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Clindamycin; Clinical Trials as Topic; Double-Blind Method; Humans; Inflammation; Random Allocation; Solutions; Tetracycline

Eighty-seven patients with moderate to severe acne were included in an 8-week randomized double-blind study to compare the efficacies of topically applied clindamycin phosphate 1% b.i.d., oral tetracyclines 500 mg b.i.d. and placebo. Patients were examined every 2 weeks and inflammatory lesions, i.e. papules and pustules were counted in the same area at each examination. Clindamycin phosphate demonstrated a highly significant 72% decrease of inflammatory lesions, as did tetracyclines with a 57% decrease, but not placebo (12%). Clindamycin phosphate was superior to tetracycline. No significant side effects were seen, in particular, no skin side effects.

Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Adolescent; Adult; Clindamycin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Tetracycline

In a double-blind study on 20 patients with acne vulgaris, 10 patients were treated with topical clindamycin and 10 patients with oral tetracycline for eight weeks. The skin and colon microflora were determined before, during and up to eight weeks after treatment. All patients improved markedly to the same extent. Topical clindamycin caused no changes in the colon flora, whereas oral tetracycline significantly suppressed the numbers of colon bacteria and four patients were colonized by new tetracycline resistant bacteria. In patients receiving tetracycline, 40% of the skin bacteria became resistant during therapy, while the corresponding figure for clindamycin was 60%. The skin flora was normalized in most patients after the treatment had stopped.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Bacteria; Clindamycin; Colon; Female; Humans; Male; Skin; Tetracycline

The aim of the present study was to evaluate different treatment schedules in some different types of acne using a quantitative counting technique. Systemic treatment with erythromycine 0.5 g daily and topical treatment with clindamycin phosphate solution 1% was found to be optimal from the efficacy/side effect ratio. The combined treatment was tried in heat-provoked and cosmetic acne with favourable results. Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne. Diazepam 4 mg daily for two weeks followed by an antihistamine in addition to erythromycine 0.5 g daily gave relatively good results in female patients with acne excorié. In acne coexisting with pronounced seborrhoic dermatitis of the face the addition of hydrocortisone cream 1% was of benefit, although Roaccutane may here be the drug of choice. In female postpubertal acne, the effect of cyproteronacetate-etynilestradiol (Diane) was not superior to treatment with erythromycine 0.5 g daily. By treating special subtypes differently, one could be able to improve the results of acne therapy.

Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Androgen Antagonists; Anti-Inflammatory Agents; Benzoyl Peroxide; Clindamycin; Cyproterone; Cyproterone Acetate; Diazepam; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Erythromycin; Ethinyl Estradiol; Female; Humans; Hydrocortisone; Male; Sulfamethoxazole; Tetracycline; Tretinoin; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination